TroFuse-010: sacituzumab tirumotecan in HR+/HER2- metastatic breast cancer

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancerПодробнее

Sacituzumab govitecan increases PFS for HR+/HER2‐ advanced breast cancer patientsПодробнее

TROPiCS-02: sacituzumab govitecan in HR+/HER- breast cancerПодробнее

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancerПодробнее

TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer | Hope RugoПодробнее

Sacituzumab govitecan effective for HR+ metastatic breast cancer regardless of Trop-2 statusПодробнее

Final OS analysis of sacituzumab govitecan in TROPiCS-02Подробнее

Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL updateПодробнее

#ESMO22 Highlights on sacituzumab govitecan in HR+/HER2- metastatic breast cancer: TROPiCS-02Подробнее

ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBCПодробнее

Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancerПодробнее

Sacituzumab govitecan for treatment-refractory metastatic breast cancerПодробнее

2nd interim analysis of OS from TROPiCS-02: SG in HR+/HER2- breast cancerПодробнее

TROPiCS-02: sacituzumab govetican improves PFS versus physicians choice for HR+/HER2- mBCПодробнее

Key challenge associated with the management of HR+/HER2- breast cancerПодробнее

ASCENT: sacituzumab govitecan shows promise in mTNBC patientsПодробнее

Treatment approach for metastatic HER2 positive breast cancerПодробнее

Helping to Address Unmet Needs in Metastatic HR+/HER2- Breast CancerПодробнее

Study of SACI-IO for Hormone Receptor Positive Metastatic Breast CancerПодробнее